Safety and Efficacy of BAFF-R CART for Refractory Neuroimmune Diseases
Trial Parameters
Brief Summary
This study is a phase Ib/IIa dose-escalation study designed to evaluate the safety, tolerability, and preliminary efficacy of autologous T cells expressing chimeric antigen receptor (CAR)-targeted B-cell activating factor receptor (BAFFR) in refractory neuroimmune diseases. The study design is divided into two parts, the first of which will be given to each patient at 3 incremental dose levels to establish the maximum tolerated dose (MTD). Each disease is expected to enroll 12 patients who meet the inclusion criteria. In the second part, 15 patients per disease will be recruited to further characterize the efficacy of the MTD.
Eligibility Criteria
Inclusion Criteria: 1\. Assessed by the investigator as having a refractory neuroimmune disease; Refractory neuroimmune diseases were defined as: 1. Poor symptom control on at least three immunosuppressive agents for more than one year; 2. Clinical evidence of at least two relapses within 12 months or three relapses within 24 months and one relapse within 12 months prior to screening. 2\. Male study participants must agree to use contraception during the treatment period for 1 year after receiving study treatment, and sperm donation is prohibited throughout the study period; 3\. In the case of females with childbearing potential, need to agree to use contraception during the treatment period and for at least 1 year after receiving study treatment. Participants must have a negative serum pregnancy test result at screening and a confirmed negative urine pregnancy test result prior to first CART treatment. Exclusion Criteria: 1. Any medical or psychiatric condition that, in the opinion of